3-bromo-5-(4-bromothien-2-yl)-N-(5-chloro-2-hydroxyphenyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxamide

MG-T-19 is an effective TIM-3 inhibitor that can suppress the interaction of TIM-3 with PtdSer, CEACAM1, and Gal-9. MG-T-19 can increase the production of tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) in peripheral blood mononuclear cells (PBMCs) from healthy donors, and enhance the ability of PBMCs to inhibit the proliferation of Kasumi-1 cells (an acute myelogenous leukemia cell line)[1].

[1] Abdel-Rahman S A, et al. Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints[J]. Science Advances, 2024, 10(42): eadq5540. DOI:10.1126/sciadv.adq5540